Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
OSE-279 by OSE Immunotherapeutics for Thyroid Cancer: Likelihood of Approval
OSE-279 is under clinical development by OSE Immunotherapeutics and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase...